Showing results (71-80 of 153) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2023
Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology GroupKatherine E Warren, Gilbert Vezina, Mark Krailo, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|November 19, 2013
A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasmaCody J Peer, Jeffrey L Brown, Timothy J Martin, et al.
Clinical Pharmacology and Therapeutics|April 1, 2011
Effect of ABCC2 (MRP2) transport function on erythromycin metabolismR M Franke, C S Lancaster, C J Peer, et al.
Cancer Chemotherapy and Pharmacology|March 13, 2014
Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancerIslam R Younis, Daniel J George, Terence J McManus, et al.
Pediatric Blood & Cancer|May 18, 2019
Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft modelsRaushan T Kurmasheva, Abhik Bandyopadhyay, Edward Favours, et al.
Molecular Cancer Therapeutics|September 18, 2020
Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal MelanomaBih-Rong Wei, Shelley B Hoover, Cody J Peer, et al.
Journal of Clinical Pharmacology|December 5, 2015
UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulationCody J Peer, Andrew K L Goey, Tristan M Sissung, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 26, 2022
Quantitation of the next-generation imipridone ONC206 in human plasma by a simple and sensitive UPLC-MS/MS assay for clinical pharmacokinetic applicationJennifer C Goodell, Sara M Zimmerman, Cody J Peer, et al.
Cancer Research|December 16, 2020
A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor ModelsShaun D Fontaine, Gary W Ashley, Peter J Houghton, et al.
Cancer Chemotherapy and Pharmacology|September 8, 2020
Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumorsKeith T Schmidt, Alwin D R Huitema, Thomas P C Dorlo, et al.
Pageof 16